Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227459 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)
A Phase 1 study of Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4), sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT02227459: Completed Phase 1 study of Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4), sponsored by Bristol-Myers Squibb.
NCT02227459 is a Phase 1 study of Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02227459, a Phase 1 study of Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4), has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of multiple doses of ND-L02-s0201 in subjects with moderate to extensive hepatic fibrosis.
Conditions Studied
Interventions
- DRUG ND-L02-s0201 Injection
Study Locations (2)
Texas
- Texas Liver Institute - Austin
Other
- Tokuda Hospital - Sofia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
What the finished NCT02227459 record still lists
NCT02227459 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4) appearing as the primary indexed condition, and to 1 intervention - of which ND-L02-s0201 Injection is the first listed.
NCT02227459 reports a single indexed study location in Texas, Other.
Frequently Asked Questions
What is clinical trial NCT02227459 about?
NCT02227459 is a clinical study titled "Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)". The purpose of this study is to evaluate the safety and tolerability of multiple doses of ND-L02-s0201 in subjects with moderate to extensive hepatic fibrosis.
What is the current status of trial NCT02227459?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-10. Estimated completion is 2016-05.
What conditions does trial NCT02227459 study?
This clinical trial studies the following conditions: Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4).
What interventions are being tested in trial NCT02227459?
The interventions under investigation include: ND-L02-s0201 Injection (DRUG).
Who is sponsoring clinical trial NCT02227459?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02227459 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02227459's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia